A retrospective, multicenter study of nintedanib with docetaxel in previously treated non-small cell lung cancer patients in Spain
Latest Information Update: 15 Oct 2019
At a glance
- Drugs Docetaxel (Primary) ; Nintedanib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2019 New trial record
- 10 Sep 2019 Results (n=120) assessing safety and efficacy of nintedanib-docetaxel combination in non-small cell lung cancer patients, presented at the 20th World Conference on Lung Cancer.
- 10 Sep 2019 Explorative analysed results presented at the 20th World Conference on Lung Cancer.